Literature DB >> 8057669

N-ras mutation and karyotypic evolution are closely associated with leukemic transformation in myelodysplastic syndrome.

S Horiike1, S Misawa, H Nakai, H Kaneko, S Yokota, M Taniwaki, Y Yamane, J Inazawa, T Abe, K Kashima.   

Abstract

We performed a longitudinal analysis of the karyotypes and N-ras gene configuration of bone marrow cells in 35 patients with myelodysplastic syndrome (MDS). Karyotypic evolution was found in eight patients, and was associated with disease progression, including leukemic transformation, in all the patients. We identified N-ras mutations in six patients, using a polymerase chain reaction (PCR) technique, in which oligonucleotide primers were constructed with induced mismatches, followed by endonuclease digestion. Direct sequencing confirmed single base substitutions at codon 12 in two patients and at codon 13 in four. The incidence of N-ras gene mutations was significantly higher in the karyotypically evolved group (five of eight patients) than in the stable group (one of 27 patients). All of five patients harboring both karyotypic evolution and an N-ras mutation showed concomitant disease progression to overt leukemia or refractory anemia with excess of blasts in transformation (RAEB-T). Two of four patients with either karyotypic evolution or N-ras mutation and six of 26 patients without any of these alterations also progressed to overt leukemia. Our results indicate that the accumulation of these genetic alterations is closely associated with leukemic transformation of MDS, although other genetic alterations may also play a key role in the remaining patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8057669

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  8 in total

1.  Preclinical efficacy of MEK inhibition in Nras-mutant AML.

Authors:  Michael R Burgess; Eugene Hwang; Ari J Firestone; Tannie Huang; Jin Xu; Johannes Zuber; Natacha Bohin; Tiffany Wen; Scott C Kogan; Kevin M Haigis; Deepak Sampath; Scott Lowe; Kevin Shannon; Qing Li
Journal:  Blood       Date:  2014-10-31       Impact factor: 22.113

2.  Clonal architecture of secondary acute myeloid leukemia.

Authors:  Matthew J Walter; Dong Shen; Li Ding; Jin Shao; Daniel C Koboldt; Ken Chen; David E Larson; Michael D McLellan; David Dooling; Rachel Abbott; Robert Fulton; Vincent Magrini; Heather Schmidt; Joelle Kalicki-Veizer; Michelle O'Laughlin; Xian Fan; Marcus Grillot; Sarah Witowski; Sharon Heath; John L Frater; William Eades; Michael Tomasson; Peter Westervelt; John F DiPersio; Daniel C Link; Elaine R Mardis; Timothy J Ley; Richard K Wilson; Timothy A Graubert
Journal:  N Engl J Med       Date:  2012-03-14       Impact factor: 91.245

Review 3.  Therapy-related myelodysplastic syndrome in a case of cutaneous adult T-cell lymphoma.

Authors:  Naofumi Fukuda; Kenji Shinohara; Ituro Ota; Kazuhiko Muraki; Yoko Shimohakamada
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

4.  The clonal origins of leukemic progression of myelodysplasia.

Authors:  T Kim; M S Tyndel; H J Kim; J-S Ahn; S H Choi; H J Park; Y-K Kim; D-H Yang; J-J Lee; S-H Jung; S Y Kim; Y H Min; J-W Cheong; S K Sohn; J H Moon; M Choi; M Lee; Z Zhang; D D H Kim
Journal:  Leukemia       Date:  2017-01-16       Impact factor: 11.528

5.  Screening of mutations in the additional sex combs like 1, transcriptional regulator, tumor protein p53, and KRAS proto-oncogene, GTPase/NRAS proto-oncogene, GTPase genes of patients with myelodysplastic syndrome.

Authors:  Carolina Leite; Lucas Delmonico; Gilda Alves; Romario José Gomes; Mariana Rodrigues Martino; Aline Rodrigues da Silva; Aline Dos Santos Moreira; Maria Christina Maioli; Luciano Rios Scherrer; Elenice Ferreira Bastos; Roberto Irineu; Maria Helena Ornellas
Journal:  Biomed Rep       Date:  2017-08-09

6.  Gene expression patterns in myelodyplasia underline the role of apoptosis and differentiation in disease initiation and progression.

Authors:  Merav Bar; Derek Stirewalt; Era Pogosova-Agadjanyan; Vitas Wagner; Ted Gooley; Nissa Abbasi; Ravi Bhatia; H Joachim Deeg; Jerald Radich
Journal:  Transl Oncogenomics       Date:  2008-05-29

7.  Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.

Authors:  Talha Badar; Keyur P Patel; Philip A Thompson; Courtney DiNardo; Koichi Takahashi; Monica Cabrero; Gautam Borthakur; Jorge Cortes; Marina Konopleva; Tapan Kadia; Zach Bohannan; Sherry Pierce; Elias J Jabbour; Farhad Ravandi; Naval Daver; Raja Luthra; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Leuk Res       Date:  2015-10-19       Impact factor: 3.156

8.  [Molecular features and prognostic value of RAS mutations in patients with myelodysplastic syndromes].

Authors:  H J Huang; B Li; T J Qin; Z F Xu; N B Hu; L J Pan; S Q Qu; D Liu; Y D Zhang; Z J Xiao
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-09-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.